Valuation: Sanofi

Market Cap 90.62B 104B 83.77B 77.39B 146B 9,960B 148B 999B 392B 4,877B 389B 381B 16,793B P/E 2026 *
11.6x
P/E 2027 * 10.7x
Enterprise Value 100B 115B 92.67B 85.62B 161B 11,019B 164B 1,105B 434B 5,395B 431B 421B 18,578B EV / Sales 2026 *
2.14x
EV / Sales 2027 * 1.92x
Free-Float
89%
Yield 2026 *
5.52%
Yield 2027 * 5.84%
1 day-2.08%
1 week+3.34%
Current month+2.39%
1 month+0.48%
3 months-2.67%
6 months-4.26%
Current year-7.24%
1 week 74.6
Extreme 74.6
77.44
1 month 71.27
Extreme 71.27
78
Current year 71.27
Extreme 71.27
84.9
1 year 71.27
Extreme 71.27
93
3 years 71.27
Extreme 71.27
111
5 years 71.27
Extreme 71.27
111
10 years 63.15
Extreme 63.15
111
Manager TitleAgeSince
Chief Executive Officer 65 01/05/2026
Director of Finance/CFO 64 01/04/2024
Chief Tech/Sci/R&D Officer 51 11/09/2023
Director TitleAgeSince
Director/Board Member 60 30/04/2019
Director/Board Member 57 28/04/2020
Director/Board Member 64 28/04/2020
Change 5-day change 1-year change 3-year change Capi.($)
-2.08%+3.34% - - 106B
-2.37%-6.67%+44.26%+156.55% 1,054B
-1.93%-5.52%+61.00%+57.93% 621B
-0.84%-3.71%+28.03%+80.28% 438B
-1.12%-3.68%+26.89%+20.58% 325B
-1.73%-3.45%+26.95%+44.09% 281B
-1.95%-13.92%+15.96%+19.76% 262B
-1.45%-2.37%-27.87%-39.87% 219B
-1.05%-3.28%+19.86%+56.55% 195B
-0.52%-4.31%+16.41%+69.04% 163B
Average -1.54%-1.70%+23.50%+51.66% 395.13B
Weighted average by Cap. -1.74%-1.69%+33.09%+77.01%

Financials

2026 *2027 *
Net sales 46.95B 53.73B 43.4B 40.1B 75.52B 5,161B 76.88B 518B 203B 2,527B 202B 197B 8,701B 50.04B 57.26B 46.26B 42.74B 80.48B 5,500B 81.94B 552B 216B 2,693B 215B 210B 9,273B
Net income 7.99B 9.14B 7.39B 6.82B 12.85B 878B 13.08B 88.09B 34.56B 430B 34.34B 33.59B 1,481B 8.9B 10.19B 8.23B 7.6B 14.32B 979B 14.58B 98.15B 38.51B 479B 38.27B 37.42B 1,650B
Net Debt 9.63B 11.02B 8.9B 8.23B 15.49B 1,059B 15.77B 106B 41.66B 518B 41.4B 40.48B 1,785B 5.52B 6.32B 5.1B 4.71B 8.88B 607B 9.04B 60.85B 23.87B 297B 23.72B 23.2B 1,023B
Logo Sanofi
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (81.8%): prescription drugs for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases; - human vaccines (18.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2025, the group had 37 production sites worldwide. Net sales are distributed geographically as follows: France (3.9%), Europe (17.1%), the United States (50.8%), China (6%) and other (22.2%).
Employees
74,846
Date Price Change Volume
13/07/26 EUR 77.03 +1.24% 1,230
10/07/26 EUR 76.09 -0.35% 1,260
09/07/26 EUR 76.36 +1.39% 2,849
08/07/26 EUR 75.31 -0.80% 413
07/07/26 EUR 75.92 +1.85% 3,450
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
77.10EUR
Average target price
96.31EUR
Spread / Average Target
+24.92%

Quarterly revenue - Rate of surprise